GlassScriptPhysician profile
Guy M Nishizawa
NPI 1548256944
$2,205.15
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $148 · 2021: $43.81 · 2022: $140 · 2023: $509 · 2024: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $418.91 | 2019-2020 | |
| Alcon Vision LLC | $340.12 | 2019-2023 | Total30 |
| Bausch & Lomb Americas INC. | $307.12 | 2023-2024 | Infuse, Biotrue One Day |
| Coopervision INC. | $244.69 | 2019-2023 | Myday Contact Lens |
| Lkc Technologies, INC. | $237.52 | 2023-2024 | |
| Glaukos Corporation | $142.34 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $124.99 | 2019 | |
| Dompe US, INC. | $118.06 | 2024 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $97.44 | 2019-2022 | |
| Allergan, INC. | $56.90 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $35.92 | 2024 | |
| Oyster Point Pharma, INC. | $34.68 | 2023 | Tyrvaya |
| Abbvie INC. | $24.48 | 2022 | |
| Optos, INC. | $21.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Nishizawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.